MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Northwest Biotherapeutics (OTCQB:NWBO)
Organization & Developments: Northwest Biotherapeutics
Parents
Northwest Biotherapeutics (OTCQB:NWBO)
Children
*Autologous immunotherapy products for cancer
*DCVax®-Prostate and DCVax®-Brain are entering FDA-allowed late stage clinical trials (2007)
*DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, loaded with tumor proteins or antigens
*Injection of these cells back into the patient as a personalized medicine cancer vaccine, initiates a potent immune response aga
2020: Northwest Biotherapeutics: Blinded By The Dazzle Of The Unblinding
2020: Northwest Biotherapeutics: Great Science, Poor Investment Idea_seekingalpha.com
2021: Northwest Bio: Nowhere To Go But Up
2021: Northwest Bio: The Endgame Is Approaching
2021: Northwest Biotherapeutics: CEO Says Unblinding Is A Work In Progress_seekingalpha.com
2022: Northwest Biotherapeutics: Biopharma's Promising Delinquent_seekingalpha.com
2022: Northwest Biotherapeutics: Data Is Done, Just Wait For Approval_ seekingalpha.com
2023: Northwest Bio: Another Small Filing Delay
2023: Northwest Bio: Data Is Great, But Nothing Else Is_ seekingalpha.com
2024: Northwest Bio wins Swiss approval for cancer vaccine
2024: Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
2024: Northwest Biotherapeutics: All Is Not Well With This One
Jumps
*Key People: Northwest Biotherapeutics
Finance & Acquisitions: Northwest Biotherapeutics